Progressive multiple sclerosis represents one of the most debilitating challenges in modern neurology. Unlike relapsing forms of the disease that exhibit clear acute inflammatory flare-ups followed by recovery, progressive disease follows an insidious trajectory of accumulating disability. Patients experience steady neurodegeneration and functional deterioration over time. Understanding the intricate biological mechanisms driving this progression is essential for clinicians aiming to improve patient outcomes. Recent insights into central nervous system pathology have catalyzed a shift toward targeted therapies and biomarker-guided management.

Complex Pathobiology Driving Progressive Multiple Sclerosis

The progression of disability in multiple sclerosis stems from distinct yet overlapping biological mechanisms. While peripheral immune activation predominates during early relapsing stages, progressive multiple sclerosis is largely fueled by compartmentalized inflammation behind a relatively closed blood-brain barrier. Chronic active lesions, often termed smoldering lesions, feature persistent microglial activation and macrophage accumulation at their expanding borders. These activated cells release reactive oxygen species, nitric oxide, and pro-inflammatory cytokines that cause slow tissue injury.

Concurrently, mitochondrial dysfunction plays a crucial role in driving virtual hypoxia within demyelinated axons. Because naked axons lack myelin insulation, they require substantially more energy to propagate action potentials. Consequently, the overwhelmed mitochondria fail to meet metabolic demands, triggering energetic failure and structural axonal degeneration. In addition, meningeal lymphoid follicles form within the subarachnoid space, producing cytotoxic factors that percolate directly into the cerebral cortex. This persistent cortical demyelination and subsequent subpial injury accelerate gray matter atrophy. Therefore, managing the disease requires interventions that address both neuroinflammation and energetic failure.

Biomarker Discovery and Diagnostic Advances in Disease Monitoring

Accurate tracking of disease progression has historically posed significant challenges for clinicians. Fortunately, breakthrough biomarker technologies now enable sensitive quantification of ongoing neuroaxonal damage and astrogliosis. Serum neurofilament light chain (sNfL) has emerged as a reliable circulating biomarker of acute axonal injury. Elevated sNfL levels correlate with subclinical disease activity and predict long-term disability worsening. Moreover, glial fibrillary acidic protein (GFAP) in serum specifically reflects astrocyte activation and diffuse neurodegeneration, making it an exceptional marker for insidious progressive biology.

Simultaneously, advanced neuroimaging modalities have revolutionized clinical assessment. High-field magnetic resonance imaging (MRI) can detect paramagnetic rim lesions (PRLs), which represent chronic active inflammation and indicate aggressive progression. Furthermore, automated volumetric MRI measures whole-brain and regional gray matter atrophy with high precision, providing objective metrics for disease monitoring. Optical coherence tomography (OCT) also evaluates retinal nerve fiber layer thinning, serving as a non-invasive window into central neuroaxonal loss. Integrating these fluid and imaging biomarkers allows clinicians to establish personalized baselines and detect subclinical progression earlier than standard clinical scales.

Current Disease-Modifying Therapies for Progressive Multiple Sclerosis

The therapeutic landscape for progressive multiple sclerosis has expanded significantly over the past decade. Previously, disease-modifying therapies developed for relapsing MS showed limited efficacy against progressive disability. However, targeted monoclonal antibodies and selective sphingosine-1-phosphate (S1P) receptor modulators have demonstrated measurable clinical benefits. Ocrelizumab, an anti-CD20 monoclonal antibody, became the first approved treatment for primary progressive MS after showing significant reductions in confirmed disability progression. It effectively depletes circulating B cells, mitigating both peripheral drive and downstream neuroinflammation.

Similarly, siponimod, a selective S1P receptor modulator targeting S1P1 and S1P5, is approved for active secondary progressive MS. Because siponimod is a small lipophilic molecule, it readily crosses the blood-brain barrier. Inside the central nervous system, it suppresses microglial activation and promotes neuroprotective pathways. It also traps circulating lymphocytes within peripheral lymph nodes. Consequently, these agents provide valuable options for slowing disability worsening. Nevertheless, their therapeutic impact remains highest in patients with active inflammatory lesions. Therefore, developing novel therapies targeting pure neurodegeneration remains an urgent priority.

Emerging Pharmacological Approaches and BTK Inhibition

To overcome the limitations of current treatments, researchers are actively investigating innovative pharmacological strategies. Among the most promising candidates are Bruton tyrosine kinase (BTK) inhibitors, such as fenebrutinib, tolebrutinib, and evobrutinib. BTK plays an essential role in downstream signaling within both B cells and innate myeloid cells. Importantly, small-molecule BTK inhibitors penetrate the blood-brain barrier effectively. This allows them to modulate chronically activated microglia and central B-cell aggregates directly within the parenchyma.

Clinical trials have revealed that BTK inhibition can suppress compartmentalized inflammation and reduce smoldering lesion activity. In addition to BTK inhibitors, researchers are exploring phosphodiesterase inhibitors like ibudilast. Ibudilast attenuates central neuroinflammation and significantly reduces brain parenchymal volume loss. Furthermore, metabolic protectors targeting mitochondrial health are under active investigation to rescue energy-depleted axons. These include coenzyme Q10 analogs and lipoic acid. These multifaceted approaches seek not only to halt inflammation but also to reinforce cellular resilience against chronic oxidative stress. As clinical trial data mature, these agents could redefine treatment algorithms for non-relapsing progressive cohorts.

Remyelination Strategies and Cell-Based Interventions

Halting tissue injury represents only one facet of modern progressive multiple sclerosis management. In contrast, functional restoration requires successful remyelination and cellular repair. Endogenous oligodendrocyte progenitor cells (OPCs) often fail to differentiate into mature myelin-producing cells within chronic lesions. Therefore, novel remyelination-promoting therapies are designed to overcome local inhibitory cues and stimulate OPC maturation. Small molecules such as clemastine fumarate and selective thyroid hormone receptor agonists have demonstrated promising remyelination signals in translational studies.

Additionally, cell-based therapies offer a revolutionary avenue for central nervous system repair and immune reset. Autologous hematopoietic stem cell transplantation (aHSCT) has demonstrated remarkable efficacy in halting aggressive progressive disease with active inflammation. It achieves this outcome by eradicating autoreactive immune repertoires. Meanwhile, mesenchymal stem cell (MSC) transplantation is being evaluated for its potent paracrine, anti-inflammatory, and trophic support properties. MSCs secrete neuroprotective growth factors that modulate local microenvironments and enhance neuronal survival. Combining remyelinating compounds with neuroprotective cell therapies could bridge the critical gap between disease arrest and neurological recovery.

Multidisciplinary Care and Lifestyle Interventions in Clinical Practice

Comprehensive management of progressive multiple sclerosis extends far beyond pharmacological agents alone. Because disability accrual affects multiple organ systems, clinicians must implement holistic, multidisciplinary care models. Physical and occupational therapy play central roles in maintaining mobility, preventing joint contractures, and managing spasticity. Regular aerobic exercise and targeted strength training stimulate neuroplasticity and improve endurance. These structured activities directly counter chronic fatigue and motor decline.

Moreover, clinicians must aggressively address comorbid cardiovascular and metabolic conditions. Hypertension, diabetes, and hyperlipidemia accelerate cerebral atrophy and worsen disability trajectories in progressive cohorts. In addition, symptom-specific management significantly improves daily quality of life. Clinicians can prescribe targeted pharmacological relief for neuropathic pain, bladder dysfunction, and cognitive impairment. Structured cognitive rehabilitation and psychological support also mitigate depression and anxiety. Ultimately, combining innovative disease-modifying therapies with proactive multidisciplinary rehabilitation provides the optimal path toward preserving function and independence.

Frequently Asked Questions

What distinguishes progressive multiple sclerosis from relapsing-remitting multiple sclerosis?

Relapsing-remitting multiple sclerosis is defined by acute inflammatory episodes followed by periods of partial or complete recovery. In contrast, progressive multiple sclerosis features steady, gradual accrual of neurological disability without distinct relapses. Pathologically, relapsing disease involves peripheral leukocyte infiltration across a disrupted blood-brain barrier. Progressive disease is characterized by compartmentalized central nervous system inflammation, microglial activation, smoldering demyelinating lesions, mitochondrial failure, and continuous neuroaxonal degeneration that drive persistent functional loss.

Which fluid biomarkers are most useful for evaluating disease progression?

Serum neurofilament light chain and glial fibrillary acidic protein represent the most valuable fluid biomarkers in progressive multiple sclerosis. Neurofilament light chain measures acute axonal transection and neuronal injury, reflecting both inflammatory activity and neurodegeneration. Glial fibrillary acidic protein specifically reflects astrogliosis and chronic injury in the central nervous system. Tracking these circulating biomarkers in blood allows clinicians to identify ongoing subclinical progression and evaluate therapeutic responsiveness objectively over time.

How do Bruton tyrosine kinase inhibitors work in progressive multiple sclerosis?

Bruton tyrosine kinase inhibitors represent an innovative oral class of therapies capable of crossing the blood-brain barrier. These small molecules inhibit signaling pathways within peripheral B cells and central microglia simultaneously. By suppressing chronic microglial activation in smoldering lesions and clearing central lymphoid aggregates, they directly target compartmentalized inflammation. Consequently, these agents offer significant promise for slowing non-relapsing disability progression and protecting vulnerable axons from ongoing neurodegenerative injury.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Chaudhary R et al. Pathobiology-guided diagnostic advances, biomarker discovery, and emerging therapeutic strategies in progressive multiple sclerosis. Dis Mon. 2026 Aug 21. doi: undefined. PMID: 42629285.
2. Bar-Or A et al. Fenebrutinib versus Teriflunomide and Ocrelizumab in Multiple Sclerosis: Phase 3 Trial Outcomes. N Engl J Med. 2026;394(7):612-624.
3. Absinta M et al. Biomarkers of neuroinflammation and neurodegeneration in progressive multiple sclerosis: from imaging to fluid analytes. Lancet Neurol. 2025;24(4):345-358.
4. Kappos L et al. Siponimod versus placebo in secondary progressive multiple sclerosis: long-term clinical and imaging outcomes. Lancet. 2024;403(10432):1123-1135.